Cover Image
市場調查報告書

美國的MA (醫療事務) 部門的評估:類風濕性關節炎

Medical Affairs Reputations (US): Rheumatoid Arthritis

出版商 FirstWord 商品編碼 351843
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的MA (醫療事務) 部門的評估:類風濕性關節炎 Medical Affairs Reputations (US): Rheumatoid Arthritis
出版日期: 2015年11月01日 內容資訊: 英文
簡介

本報告以類風濕性關節炎治療藥的主要9個產品相關的醫療事務 (MA) 團隊上,美國的100名醫生為對象加以調查,彙整其對各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象的企業·品牌

  • AbbVie
    • Humira (Adalimumab)
  • Amgen
    • Enbrel (依那西普(Etanercept))
  • Bristol-Myers Squibb
    • Orencia (abatacept)
  • Janssen Biotech
    • Remicade (Infliximab)
    • Simponi (golimumab)
  • Pfizer
    • Xeljanz (tofacitinib)
  • Roche
    • Actemra (tocilizumab)
    • Rituxan (Rituximab)
  • UCB
    • Cimzia (certolizumab pegol)

調查課題

  • 各公司MA團隊對類風濕性關節炎的評估點
  • 互動的品質·效能·滿意度的個別分析·比較分析
  • 各公司MA團隊與類風濕性關節炎的互動:醫生的印象
  • 不足的資訊·必須改善的點
  • 醫生想與MA團隊取得聯繫的頻率
目錄
Product Code: 596200405

Is your rheumatoid arthritis Medical Affairs team leading the pack or following on behind?

How are Medical Affairs teams from challenger brands shaping up when compared with those from well-established products in the rheumatoid arthritis category? How close is the pack? Or are there brands at the top and bottom ends set apart from everyone else on how well (or badly) they are regarded by physicians?

See where your Medical Affairs team comes in the latest ranking, together with insights into what services matter to physicians and where they would like further improvements.

Don't forget, if you also buy the EU5 version you'll get a free comparison report, saving you time understanding and analysing the differences uncovered between these crucial markets.

Brands covered

  • AbbVie
    • Humira (adalimumab)
  • Amgen
    • Enbrel (etanercept)
  • Bristol-Myers Squibb
    • Orencia (abatacept)
  • Janssen Biotech
    • Remicade (infliximab)
    • Simponi (golimumab)
  • Pfizer
    • Xeljanz (tofacitinib)
  • Roche
    • Actemra (tocilizumab)
    • Rituxan (rituximab)
  • UCB
    • Cimzia (certolizumab pegol)

Top Takeaways

  • One team stands out from the rest: One brand forges ahead on overall quality of interactions, but still has one key area to focus on for improvement
  • Report reveals the services that really matter: Physicians rank the services that they value the most so you can understand essential requirements
  • Core needs generally met: The key issues where physicians rely on Medical Affairs teams for help are awarded positive scores, even for the lower-ranking teams
  • Still room for improvement: Need-gap analysis reveals that in areas of secondary importance, physicians are still seeking more help from the Medical Affairs teams
  • Important needs of US and EU5 physicians vary: Differences are revealed in which services matter most to physicians. Get the comparison report free when you buy both the US and EU report.
  • Some information needs unfulfilled: See where you need to improve so that physicians are able to make informed decisions when assessing competing treatments

Key issues explored

  • How physicians rate your rheumatoid arthritis Medical Affairs team
  • Interaction quality, performance and satisfaction measured and compared both overall and on a drug-by-drug basis
  • How well physicians remember their interactions with your rheumatoid arthritis Medical Affairs team
  • Where physicians see information as lacking for your brand so you know where you need to improve. See where there are outstanding information needs for your brand that will assist physicians when they are making decisions about competing treatments
  • How often physicians like to be contacted and the way they prefer to conduct their interactions with Medical Affairs teams

Methodology

  • 100 rheumatologists across US participated in this study
  • Data was collected via a 15-minute internet-based questionnaire

Participants screened to ensure they:

  • See at least 5 patients for rheumatoid arthritis in a typical month
  • Have been in active practice between 3-35 years
  • Devote at least 50% of time to direct patient care
  • Have had an interaction with a Medical Affairs professional in the past 6 months for at least one of the listed products
Back to Top